Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis

Fig. 3

Mean A, B CXCR5-positive B and C, D cTfh cell counts in the single ascending dose and multiple ascending dose cohorts (PD analysis population). The PD analysis population included all patients who received at least one dose of the study treatment and had at least one PD measurement. A single IV dose was administered in SAD cohorts (designated Day 1), and multiple SC doses were administered in MAD cohorts (Day 1 and 29); the study duration including follow-up was 4–10 months from the screening. The plots presented are semi-logarithmic. cTfh circulating follicular T helper-like, CXCR5 C-X-C chemokine receptor type 5, IV intravenous, MAD multiple ascending dose, PD pharmacodynamic, SAD single ascending dose, SC subcutaneous

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us